What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.

Home diagnostics need regulatory trust. TytoCare’s FDA De Novo win tests whether AI can move ear exams beyond video visits.

BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.

Ozelle’s AI-powered CBM platform debuts at WHX Dubai 2026. Discover how modular, guided diagnostics are transforming primary and veterinary care workflows.

Find out why PathoCare’s $1.75B valuation and expanded $50M financing round could signal a breakthrough moment for AI-powered point-of-care diagnostics.

The rapid progress of artificial intelligence in medical imaging is creating fresh optimism among healthcare leaders seeking to close the persistent equity gap in breast cancer screening. The regulatory push by Lunit, a Seoul-based AI diagnostics firm, for its Lunit INSIGHT Risk model, which estimates a woman’s five-year breast cancer risk directly from mammogram images, […]

Geneva Private Equity has launched NXXIM, a new AI-powered enterprise medical imaging platform designed to unify radiology, pathology, genomics, and electronic health record data into a single, real-time diagnostic environment. The investment-backed venture will pilot its platform in clinical settings in 2026, aiming to streamline fragmented workflows and reduce time-to-diagnosis for large health systems. What […]